A Phase 2 interventional study of ATI-50002 high dose and ATI-50002 low dose in Alopecia Areata, sponsored by Aclaris Therapeutics, Inc.. Terminated at 23 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-06-05.
Sponsored by Aclaris Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.
Among the 98 studies in Alopecia Areata with a site in United States, this one is the 20th largest by enrollment of the 84 interventional ones that give a count, is one of 3 that started in 2017, is one of 42 in phase 2, and was the 34th registered.
221 studies on the registry are indexed under Alopecia Areata; 62 are open to participants now.
Browse Alopecia Areata studies →21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:
AbbVie · Sites in United States, Australia, Japan and 1 more country
Ages 6–17
Pfizer · Sites in United States, Canada, China and 2 more countries
Ages 12+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18–60
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
Almirall, S.A. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 42 Alopecia Areata studies recruiting now, 17 (40%) set no upper age limit and 21 (50%) stop at 75 or younger; 20 take children under 18; 6 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 48 · Phase 3 16 · Phase 4 8
First in 1997; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 46 across the 84 interventional studies, 2,300 across the 14 observational. Of the 60 that completed or were terminated, 42 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 98 have an industry lead sponsor. The 10 most frequent:
Aclaris Therapeutics, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 22 (88%) have results posted.
Aclaris Therapeutics, Inc. has 3 studies filed under Alopecia Areata — fewer than ten, so there is no comparison to draw.
10 of the studies in Alopecia Areata with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT03898479Phase 3Sun Pharmaceutical Industries, Inc.Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2027-05 |
| NCT06826196Aldena TherapeuticsA Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata | 2026-11 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
| NCT06602232Dren BioA Study of DR-01 in Subjects With Alopecia Areata and Vitiligo | 2027-05 |
Add all 10 to your calendar (.ics) → With an account.
Among the 98 studies in Alopecia Areata with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary:
Secondary:
Primary:
Secondary:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
High dose active
Drug: ATI-50002 high dose
low dose active
Drug: ATI-50002 low dose
placebo
Drug: Placebo
Topical solution
Topical solution
Topical solution
Percent Change From Baseline in the Severity of Alopecia Tool Score at Week 24
The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss). A negative change in the SALT score over time represents hair regrowth. The primary efficacy variable was the percent change from baseline in SALT score at Week 24. This was calculated as the mean of the changes from Baseline (Visit 2) SALT score to Week 24 (Visit 10) SALT score, divided by Baseline SALT score and expressed as a percentage.
Time frame: Baseline - Week 24
Percent Change From Baseline in the Alopecia Density and Extent Score at Week 24
The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness). Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness). A negative change in the ALODEX score over time represents hair regrowth.
Time frame: Baseline - Week 24
Mean Change From Baseline in Severity of Alopecia Tool Score at Week 24
The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair. Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss). A negative change in the SALT score over time represents hair regrowth.
Time frame: Baseline - Week 24
Mean Change From Baseline in Alopecia Density and Extent Score at Week 24
The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness). Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness). A negative change in the ALODEX score over time represents hair regrowth.
Time frame: Baseline - Week 24
Proportion of Subjects Achieving ≥50% Hair Regrowth Based on Severity of Alopecia Tool Scores at Week 24
A summary of the proportion of subjects in each treatment arm achieving ≥50% hair regrowth compared with baseline using Severity of Alopecia Tool scores at Week 24 is presented.
Time frame: Baseline - Week 24
Proportion of Subjects Achieving ≥50% Hair Regrowth Based on Alopecia Density and Extent Scores at Week 24
A summary of the proportion of subjects in each treatment arm achieving ≥50% hair regrowth compared with baseline using Alopecia Density and Extent scores at Week 24 is presented.
Time frame: Baseline - Week 24
Proportion of Subjects With ≥2 Point Improvement in Scalp Patient Reported Outcome for Target Patch at Week 24
The Scalp Patient Reported Outcome for Target Patch assesses the appearance of the subject's target patch (identified by the subject as his or her most bothersome area of scalp hair loss at Baseline) and was completed by subjects at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, scalp of the target patch completely covered with hair" to "no hair, scalp of the target patch completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. A summary of the proportion of subjects with ≥2 point improvement in Subject Target Patch assessment at Week 24 compared to baseline is presented.
Time frame: Baseline - Week 24
Proportion of Subjects With ≥1 Point Improvement in Scalp Patient Reported Outcome for Entire Scalp at Week 24
The Scalp Patient Reported Outcome for Entire Scalp assesses the appearance of the subject's whole scalp and was completed by subjects at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, whole scalp completely covered with hair" to "no hair, whole scalp completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. A summary of the proportion of subjects with ≥1 point improvement in Subject Entire Scalp assessment at Week 24 compared to baseline is presented.
Time frame: Baseline - Week 24
Proportion of Subjects With ≥2-Point Improvement in Scalp Clinician Reported Outcome for Target Patch at Week 24
The Scalp Clinician Reported Outcome for Target Patch provides the investigator's assessment of the appearance of the subject's target patch (identified by the subject as his or her most bothersome area of scalp hair loss at Baseline) and was completed by investigators at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, scalp of the target patch completely covered with hair" to "no hair, scalp of the target patch completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. A summary of the proportion of subjects with ≥2 point improvement in Clinician Target Patch assessment at Week 24 compared to baseline is presented.
Time frame: Baseline - Week 24
Change From Baseline in Scalp Clinician Reported Outcome for Entire Scalp at Week 24
The Scalp Clinician Reported Outcome for Entire Scalp assesses the appearance of the subject's whole scalp and was completed by investigators at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, whole scalp completely covered with hair" to "no hair, whole scalp completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points.
Time frame: Baseline - Week 24
Change From Baseline in the Physician Global Impression of Severity (PhGIS) of Patchy Alopecia Areata at Week 24
The Physician Global Impression of Severity (PhGIS) is a 5-point descriptive scale completed by investigators at Baseline, Week 4, Week 12, and Week 24 and is used to capture the investigator's assessment of the subject's disease severity at a particular timepoint. Scores of 1 to 5 are assigned to responses Mild to Extremely Severe, respectively. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points.
Time frame: Baseline - Week 24
Change From Baseline in the Subject Global Impression of Severity of Patchy Alopecia Areata at Week 24
The Subject Global Impression of Severity (SGIS) is a 5-point descriptive scale completed by subjects at Baseline, Week 4, Week 12, and Week 24 and is used to capture the subject's assessment of disease severity at a particular timepoint. Scores of 1 to 5 are assigned to responses Mild to Extremely Severe, respectively. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points.
Time frame: Baseline - Week 24
Alopecia Impact Assessment Patient Reported Outcome Change From Baseline at Week 24
The Alopecia Impact Assessment (AIA) is a 13-item patient reported outcome questionnaire which measures the subject's experience with impacts related to alopecia areata in managing appearance, worry, sadness, loss of confidence, self-consciousness, embarrassment, feeling unattractive, limitation of social activities, limitation of physical activities, unwanted attention, sweat in eyes, debris in eyes, and debris in nose. The AIA was completed by subjects at Baseline, Week 4, Week 12, and Week 24 and has a recall period of "over the past seven days". An 11-point NRS with anchors "0 - Not at all \[impact\]" and "10 - Extremely \[impact\]" (e.g., "Not at all bothersome" and "Extremely bothersome"; "Not at all worried" and "Extremely worried") is utilized. The AIA produces single-item (0-10) and mean total (0-10) scores, with higher scores indicating higher levels of impact.
Time frame: Baseline - Week 24
Subject Global Impression of Treatment Satisfaction at Week 24
The Subject Global Impression of Treatment Satisfaction (SGITS) is a 7-point descriptive scale completed by subjects at Week 12 and Week 24. Scale response options ranged from "1. Extremely Satisfied" to "7. Extremely Dissatisfied" and are used to capture how satisfied or dissatisfied they are with the study medication treatment received for their alopecia areata.
Time frame: Week 24
Change in Dermatology Life Quality Index Total Score Between Baseline and Week 24
The 10 question Dermatology Life Quality Index (DLQI) questionnaire was completed by subjects at Baseline, Week 4, Week 12, and Week 24. When completing the questionnaire, subjects were instructed to think of their hair loss in place of "skin problem" and "skin" as referenced in the questionnaire. Possible summary scores could range from 0 to 30 with higher scores indicating a worse outcome.
Time frame: Baseline - Week 24
Physician Global Impression of Change at Week 24
The Physician Global Impression of Change (PhGIC) is a 7-point descriptive scale completed by investigators at Week 24. Scale response options ranged from "1. Very much improved" to "7. Very much worse" and are used to capture the investigator's overall impression of change for the subject's alopecia during the treatment period.
Time frame: Week 24
Subject Global Impression of Change at Week 24
The Subject Global Impression of Change (SGIC) is a 7-point descriptive scale completed by subjects at Week 24. Scale response options ranged from "1. Very much improved" to "7. Very much worse" and are used to capture the subject's overall impression of change for his/her alopecia during the treatment period.
Time frame: Week 24
| Milestone | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Started | 43 | 44 | 42 |
| Completed | 26 | 31 | 35 |
| Not completed | 17 | 13 | 7 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Lost to follow-up | 3 | 4 | 3 |
| Withdrew: Withdrawal by subject | 10 | 6 | 4 |
| Withdrew: Incomplete efficacy data collection | 1 | 1 | 0 |
| Milestone | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Started | 0 | 0 | 61 |
| Completed | 0 | 0 | 33 |
| Not completed | 0 | 0 | 28 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 5 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 17 |
| Withdrew: Subject noncompliance | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 |
The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss). A negative change in the SALT score over time represents hair regrowth. The primary efficacy variable was the percent change from baseline in SALT score at Week 24. This was calculated as the mean of the changes from Baseline (Visit 2) SALT score to Week 24 (Visit 10) SALT score, divided by Baseline SALT score and expressed as a percentage.
| score on a scale | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Percent Change From Baseline in the Severity of Alopecia Tool Score at Week 24 | -18.54 ± 4.705 | -4.66 ± 4.707 | -9.22 ± 4.784 |
The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness). Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness). A negative change in the ALODEX score over time represents hair regrowth.
| score on a scale | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Percent Change From Baseline in the Alopecia Density and Extent Score at Week 24 | -14.75 ± 4.508 | -8.15 ± 4.511 | -11.52 ± 4.584 |
The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair. Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss). A negative change in the SALT score over time represents hair regrowth.
| score on a scale | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Mean Change From Baseline in Severity of Alopecia Tool Score at Week 24 | -6.47 ± 2.071 | -1.95 ± 2.074 | -2.94 ± 2.107 |
The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness). Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness). A negative change in the ALODEX score over time represents hair regrowth.
| score on a scale | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Mean Change From Baseline in Alopecia Density and Extent Score at Week 24 | -4.91 ± 2.129 | -3.36 ± 2.131 | -4.98 ± 2.165 |
A summary of the proportion of subjects in each treatment arm achieving ≥50% hair regrowth compared with baseline using Severity of Alopecia Tool scores at Week 24 is presented.
| Participants | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Proportion of Subjects Achieving ≥50% Hair Regrowth Based on Severity of Alopecia Tool Scores at Week 24 | 5 | 7 | 8 |
A summary of the proportion of subjects in each treatment arm achieving ≥50% hair regrowth compared with baseline using Alopecia Density and Extent scores at Week 24 is presented.
| Participants | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Proportion of Subjects Achieving ≥50% Hair Regrowth Based on Alopecia Density and Extent Scores at Week 24 | 6 | 8 | 8 |
The Scalp Patient Reported Outcome for Target Patch assesses the appearance of the subject's target patch (identified by the subject as his or her most bothersome area of scalp hair loss at Baseline) and was completed by subjects at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, scalp of the target patch completely covered with hair" to "no hair, scalp of the target patch completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. A summary of the proportion of subjects with ≥2 point improvement in Subject Target Patch assessment at Week 24 compared to baseline is presented.
| Participants | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Proportion of Subjects With ≥2 Point Improvement in Scalp Patient Reported Outcome for Target Patch at Week 24 | 6 | 8 | 9 |
The Scalp Patient Reported Outcome for Entire Scalp assesses the appearance of the subject's whole scalp and was completed by subjects at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, whole scalp completely covered with hair" to "no hair, whole scalp completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. A summary of the proportion of subjects with ≥1 point improvement in Subject Entire Scalp assessment at Week 24 compared to baseline is presented.
| Participants | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Proportion of Subjects With ≥1 Point Improvement in Scalp Patient Reported Outcome for Entire Scalp at Week 24 | 13 | 10 | 9 |
The Scalp Clinician Reported Outcome for Target Patch provides the investigator's assessment of the appearance of the subject's target patch (identified by the subject as his or her most bothersome area of scalp hair loss at Baseline) and was completed by investigators at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, scalp of the target patch completely covered with hair" to "no hair, scalp of the target patch completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. A summary of the proportion of subjects with ≥2 point improvement in Clinician Target Patch assessment at Week 24 compared to baseline is presented.
| Participants | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Proportion of Subjects With ≥2-Point Improvement in Scalp Clinician Reported Outcome for Target Patch at Week 24 | 6 | 10 | 9 |
The Scalp Clinician Reported Outcome for Entire Scalp assesses the appearance of the subject's whole scalp and was completed by investigators at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, whole scalp completely covered with hair" to "no hair, whole scalp completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points.
| Participants | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Better by 4 points | 0 | 0 | 0 |
| Better by 3 points | 0 | 0 | 1 |
| Better by 2 points | 1 | 2 | 2 |
| Better by 1 points | 11 | 9 | 8 |
| No change | 27 | 27 | 23 |
| Worse by 1 point | 4 | 5 | 7 |
| Worse by 2 point | 0 | 1 | 1 |
| Worse by 3 point | 0 | 0 | 0 |
| Worse by 4 point | 0 | 0 | 0 |
The Physician Global Impression of Severity (PhGIS) is a 5-point descriptive scale completed by investigators at Baseline, Week 4, Week 12, and Week 24 and is used to capture the investigator's assessment of the subject's disease severity at a particular timepoint. Scores of 1 to 5 are assigned to responses Mild to Extremely Severe, respectively. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points.
| Participants | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Better by 4 points | 0 | 0 | 0 |
| Better by 3 points | 0 | 0 | 0 |
| Better by 2 points | 5 | 4 | 4 |
| Better by 1 point | 9 | 10 | 12 |
| No change | 27 | 26 | 19 |
| Worse by 1 point | 1 | 3 | 5 |
| Worse by 2 points | 1 | 1 | 1 |
| Worse by 3 points | 0 | 0 | 1 |
| Worse by 4 points | 0 | 0 | 0 |
The Subject Global Impression of Severity (SGIS) is a 5-point descriptive scale completed by subjects at Baseline, Week 4, Week 12, and Week 24 and is used to capture the subject's assessment of disease severity at a particular timepoint. Scores of 1 to 5 are assigned to responses Mild to Extremely Severe, respectively. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points.
| Participants | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Better by 4 points | 0 | 1 | 0 |
| Better by 3 points | 1 | 2 | 3 |
| Better by 2 points | 6 | 5 | 5 |
| Better by 1 point | 9 | 4 | 9 |
| No change | 11 | 20 | 17 |
| Worse by 1 point | 14 | 8 | 7 |
| Worse by 2 points | 2 | 4 | 1 |
| Worse by 3 points | 0 | 0 | 0 |
| Worse by 4 points | 0 | 0 | 0 |
The Alopecia Impact Assessment (AIA) is a 13-item patient reported outcome questionnaire which measures the subject's experience with impacts related to alopecia areata in managing appearance, worry, sadness, loss of confidence, self-consciousness, embarrassment, feeling unattractive, limitation of social activities, limitation of physical activities, unwanted attention, sweat in eyes, debris in eyes, and debris in nose. The AIA was completed by subjects at Baseline, Week 4, Week 12, and Week 24 and has a recall period of "over the past seven days". An 11-point NRS with anchors "0 - Not at all \[impact\]" and "10 - Extremely \[impact\]" (e.g., "Not at all bothersome" and "Extremely bothersome"; "Not at all worried" and "Extremely worried") is utilized. The AIA produces single-item (0-10) and mean total (0-10) scores, with higher scores indicating higher levels of impact.
| score on a scale | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Alopecia Impact Assessment Patient Reported Outcome Change From Baseline at Week 24 | -0.8 ± 2.21 | -0.8 ± 2.26 | -1.0 ± 2.30 |
The Subject Global Impression of Treatment Satisfaction (SGITS) is a 7-point descriptive scale completed by subjects at Week 12 and Week 24. Scale response options ranged from "1. Extremely Satisfied" to "7. Extremely Dissatisfied" and are used to capture how satisfied or dissatisfied they are with the study medication treatment received for their alopecia areata.
| Participants | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| 1. Extremely satisfied | 5 | 8 | 9 |
| 2. Moderately satisfied | 6 | 5 | 7 |
| 3. A little satisfied | 5 | 7 | 3 |
| 4. Neither satisfied or dissatisfied | 5 | 8 | 6 |
| 5. A little dissatisfied | 3 | 4 | 2 |
| 6. Moderately dissatisfied | 5 | 3 | 4 |
| 7. Extremely dissatisfied | 9 | 6 | 7 |
The 10 question Dermatology Life Quality Index (DLQI) questionnaire was completed by subjects at Baseline, Week 4, Week 12, and Week 24. When completing the questionnaire, subjects were instructed to think of their hair loss in place of "skin problem" and "skin" as referenced in the questionnaire. Possible summary scores could range from 0 to 30 with higher scores indicating a worse outcome.
| score on a scale | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| Change in Dermatology Life Quality Index Total Score Between Baseline and Week 24 | -0.5 ± 7.64 | -1.1 ± 4.07 | -2.2 ± 5.46 |
The Physician Global Impression of Change (PhGIC) is a 7-point descriptive scale completed by investigators at Week 24. Scale response options ranged from "1. Very much improved" to "7. Very much worse" and are used to capture the investigator's overall impression of change for the subject's alopecia during the treatment period.
| Participants | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| 1. Very much improved | 2 | 1 | 6 |
| 2. Much improved | 3 | 3 | 2 |
| 3. A little improved | 10 | 7 | 9 |
| 4. No change | 8 | 12 | 8 |
| 5. A little worse | 0 | 4 | 4 |
| 6. Much worse | 1 | 1 | 1 |
| 7. Very much worse | 1 | 2 | 2 |
The Subject Global Impression of Change (SGIC) is a 7-point descriptive scale completed by subjects at Week 24. Scale response options ranged from "1. Very much improved" to "7. Very much worse" and are used to capture the subject's overall impression of change for his/her alopecia during the treatment period.
| Participants | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution |
|---|---|---|---|
| 1. Very much improved | 4 | 1 | 3 |
| 2. Much improved | 2 | 4 | 6 |
| 3. A little improved | 8 | 10 | 5 |
| 4. No change | 3 | 4 | 8 |
| 5. A little worse | 4 | 4 | 6 |
| 6. Much worse | 3 | 3 | 1 |
| 7. Very much worse | 1 | 1 | 4 |
Collected over Double blind period = 6 months; Open label extension period = 6 months; Reporting of non-serious AEs started with each subject's first study medication application and continued until the end of the subject's last study visit. Reporting for SAEs started when the subject signed the informed consent document and continued until the end of the subject's last visit.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle Topical Solution (Double Blind Period) | 0/43 (0%) | 0/43 (0%) | 21/43 (48.8%) |
| ATI-50002 0.12% Topical Solution (Double Blind Period) | 0/44 (0%) | 2/44 (4.5%) | 19/44 (43.2%) |
| ATI-50002 0.46% Topical Solution (Double Blind Period) | 0/42 (0%) | 0/42 (0%) | 14/42 (33.3%) |
| ATI-50002 0.46% Topical Solution (Open Label Extension Period) | 0/59 (0%) | 0/59 (0%) | 27/59 (45.8%) |
| Event | Vehicle Topical Solution (Double Blind Period) | ATI-50002 0.12% Topical Solution (Double Blind Period) | ATI-50002 0.46% Topical Solution (Double Blind Period) | ATI-50002 0.46% Topical Solution (Open Label Extension Period) |
|---|---|---|---|---|
| Application site lacerationGeneral disorders | 0/43 | 1/44 | 0/42 | 0/59 |
| Polyneuropathy idiopathic progressiveNervous system disorders | 0/43 | 1/44 | 0/42 | 0/59 |
| Event | Vehicle Topical Solution (Double Blind Period) | ATI-50002 0.12% Topical Solution (Double Blind Period) | ATI-50002 0.46% Topical Solution (Double Blind Period) | ATI-50002 0.46% Topical Solution (Open Label Extension Period) |
|---|---|---|---|---|
| Application site pruritisGeneral disorders | 3/43 | 1/44 | 4/42 | 2/59 |
| Upper respiratory tract infectionInfections and infestations | 0/43 | 2/44 | 4/42 | 5/59 |
| White blood cells urine positiveInvestigations | 3/43 | 1/44 | 0/42 | 0/59 |
| DiarrhoeaGastrointestinal disorders | 2/43 | 3/44 | 0/42 | 2/59 |
| Blood creatine phosphokinase increasedInvestigations | 0/43 | 0/44 | 0/42 | 4/59 |
| InfluenzaInfections and infestations | 1/43 | 0/44 | 2/42 | 2/59 |
| NasopharyngitisInfections and infestations | 2/43 | 2/44 | 1/42 | 1/59 |
| Urinary tract infectionInfections and infestations | 2/43 | 0/44 | 1/42 | 0/59 |
| Blood uric acid increasedInvestigations | 2/43 | 0/44 | 0/42 | 0/59 |
| Lymphocyte count decreasedInvestigations | 2/43 | 0/44 | 0/42 | 0/59 |
| Age, Categorical(Participants) | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution | Total |
|---|---|---|---|---|
| <=18 years | 3 | 0 | 2 | 5 |
| Between 18 and 65 years | 36 | 40 | 37 | 113 |
| >=65 years | 4 | 4 | 3 | 11 |
| Age, Continuous(years) | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution | Total |
|---|---|---|---|---|
| Mean | 42.0 ± 16.58 | 42.1 ± 13.92 | 40.5 ± 14.99 | 41.5 ± 15.09 |
| Sex: Female, Male(Participants) | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution | Total |
|---|---|---|---|---|
| Female | 15 | 13 | 18 | 46 |
| Male | 28 | 31 | 24 | 83 |
| Ethnicity (NIH/OMB)(Participants) | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution | Total |
|---|---|---|---|---|
| Hispanic or Latino | 8 | 4 | 7 | 19 |
| Not Hispanic or Latino | 23 | 26 | 23 | 72 |
| Unknown or Not Reported | 12 | 14 | 12 | 38 |
| Race (NIH/OMB)(Participants) | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 11 | 10 | 7 | 28 |
| White | 32 | 29 | 31 | 92 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 3 | 5 |
| Region of Enrollment(participants) | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution | Total |
|---|---|---|---|---|
| United States | 43 | 43 | 43 | 129 |
| Fitzpatrick Skin Type(Participants) | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution | Total |
|---|---|---|---|---|
| I - Always Burns | 2 | 3 | 2 | 7 |
| II - Burns Easily | 12 | 16 | 14 | 42 |
| III - Burns Moderately | 13 | 9 | 9 | 31 |
| IV - Burns Minimally | 6 | 6 | 8 | 20 |
| V - Rarely Burns | 6 | 7 | 6 | 19 |
| VI - Never Burns | 4 | 3 | 3 | 10 |
| Duration of Current Episode of Alopecia Areata(weeks) | Vehicle Topical Solution | ATI-50002 0.12% Topical Solution | ATI-50002 0.46% Topical Solution | Total |
|---|---|---|---|---|
| Mean | 127.8 ± 104.13 | 160.7 ± 140.67 | 156.3 ± 140.95 | 148.3 ± 129.55 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2017 to primary completion in Apr 2019, 16 months.
Results were first posted in Jun 2020, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ifidancitinib